327 related articles for article (PubMed ID: 33514736)
1. The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3.
Vaughan CA; Singh S; Subler MA; Windle JJ; Inoue K; Fry EA; Pillappa R; Grossman SR; Windle B; Andrew Yeudall W; Deb SP; Deb S
Nat Commun; 2021 Jan; 12(1):704. PubMed ID: 33514736
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
3. Addiction of lung cancer cells to GOF p53 is promoted by up-regulation of epidermal growth factor receptor through multiple contacts with p53 transactivation domain and promoter.
Vaughan CA; Pearsall I; Singh S; Windle B; Deb SP; Grossman SR; Yeudall WA; Deb S
Oncotarget; 2016 Mar; 7(11):12426-46. PubMed ID: 26820293
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
5. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
6. Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
Vaughan CA; Frum R; Pearsall I; Singh S; Windle B; Yeudall A; Deb SP; Deb S
Biochem Biophys Res Commun; 2012 Nov; 428(1):6-10. PubMed ID: 22989750
[TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3.
Xie S; Wang Q; Wu H; Cogswell J; Lu L; Jhanwar-Uniyal M; Dai W
J Biol Chem; 2001 Sep; 276(39):36194-9. PubMed ID: 11447225
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain.
Suzuki S; Tsutsumi S; Chen Y; Ozeki C; Okabe A; Kawase T; Aburatani H; Ohki R
Cancer Sci; 2020 Feb; 111(2):451-466. PubMed ID: 31834974
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?
Oduah EI; Grossman SR
Cancer Biol Ther; 2020 Apr; 21(4):293-302. PubMed ID: 32041464
[TBL] [Abstract][Full Text] [Related]
12. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.
Xie S; Wu H; Wang Q; Cogswell JP; Husain I; Conn C; Stambrook P; Jhanwar-Uniyal M; Dai W
J Biol Chem; 2001 Nov; 276(46):43305-12. PubMed ID: 11551930
[TBL] [Abstract][Full Text] [Related]
13. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
14. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR
J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363
[TBL] [Abstract][Full Text] [Related]
15. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
16. Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response.
Li Z; Niu J; Uwagawa T; Peng B; Chiao PJ
J Biol Chem; 2005 Apr; 280(17):16843-50. PubMed ID: 15671037
[TBL] [Abstract][Full Text] [Related]
17. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
18. Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.
Torchia EC; Caulin C; Acin S; Terzian T; Kubick BJ; Box NF; Roop DR
Oncogene; 2012 May; 31(21):2680-90. PubMed ID: 21963848
[TBL] [Abstract][Full Text] [Related]
19. Dichotomous transactivation domains contribute to growth inhibitory and promotion functions of TAp73.
Li D; Kok CYL; Wang C; Ray D; Osterburg S; Dötsch V; Ghosh S; Sabapathy K
Proc Natl Acad Sci U S A; 2024 May; 121(21):e2318591121. PubMed ID: 38739802
[TBL] [Abstract][Full Text] [Related]
20. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
